Simone Susanne Krebs, M.D., M.S.
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor (Joint Appointment), Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Board Certifications
| 2017 | American Board of Nuclear Medicine |
Honors & Awards
| 2025 | Featured Article of Month, Journal of Nuclear Medicine |
| 2024 | Saul Hertz Young Investigator Award, 7th Theranostics World Congress |
| 2023 | Leadership Academy, Society of Nuclear Medicine and Molecular Imaging |
| 2022 | 1st Place prize in Basic Track, Society of Nuclear Medicine and Molecular Imaging |
| 2021 | NIH R37 (MERIT) Award, National Institutes of Health |
| 2021 | EANM Springer Prize 2020 - EJNMMI Best Paper 2020 for the manuscript entitled “Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors”, European Association of Nuclear Medicine/ European Journal of Nuclear Medicine and Molecular Imaging |
| 2021 | One To Watch, Society of Nuclear Medicine and Molecular Imaging |
| 2020 | NIH SPORE Lymphoma Career Enhancement Program Award, National Institutes of Health |
| 2018 | Larry E. Kun, MD Award of Academic Excellence and Dedication to Cures, TeamConnor Childhood Cancer Foundation |
| 2016 | NIH K12 Paul Calabresi Career Development Award for Clinical Oncology Program, National Institutes of Health |
| 2016 | NIH K30 Clinical Research Methodology Curriculum, National Institutes of Health |
| 2015 | Best Poster – Travel Grant for “First in-Human Trial of Dasatinib-Tracer PET Imaging: Preliminary Results in Cancer Patients”, American College of Nuclear Medicine and Society of Nuclear Medicine and Molecular Imaging |
| 2008 | Federation of European Neuroscience Societies (FENS) Award |
Selected Publications
Peer-Reviewed Articles
- Gajecki, L, Lebedeva, IV, Liao, YR, Ambriz, D, Carter, LM, Kumpf, M, Lovibond, S, Hachey, JS, Graham, MS, Postow, MA, Lewis, JS, Andrew, DP, Baca, M, Schöder, H, Larson, S, Veach, DR, Krebs, SS. IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies. J Nucl Med 66(4):605-611, 2025. e-Pub 2025. PMID: 39978817.
- Lafontaine, D, Augensen, F, Kesner, A, Vincent, R, Kirov, AS, Krebs, SS, Schöder, H, Humm, JL. Machine-learning based quantification of lung shunt fraction from 99mTc-MAA SPECT/CT for selective internal radiation therapy of liver tumors using TriDFusion (3DF). EJNMMI Physics 12(1):22, 2025. e-Pub 2025. PMID: 40064717.
- Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, Guo HF, Le Roux AB, Gajecki L, Krebs S, Yang G, Ouerfelli O, Zanzonico PB, Fung EK, St Jean S, Carrasco SE, Jungbluth A, Cheung NKV, Larson SM, Veach DR, Cheal SM. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent (177)Lu-Labeled Radiohapten. J Nucl Med 65(10):1611-1618, 2024. e-Pub 2024. PMID: 39168519.
- Pasquini L, Jenabi M, Graham M, Peck KK, Schoder H, Holodny AI, Krebs S. Tumors Affect the Metabolic Connectivity of the Human Brain Measured by 18 F-FDG PET. Clin Nucl Med 49(9):822-829, 2024. e-Pub 2024. PMID: 38693648.
- Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Kesner AL, Cheung NV, Schoder H, Gajecki L, Cheal SM, Larson SM, Scheinberg DA, Krebs S. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics 13(15):5469-5482, 2023. e-Pub 2023. PMID: 37908719.
- McLaughlin LA, Yildirim O, Rosenblum MK, Imber BS, Haseltine JM, Zelefsky MJ, Schoder H, Morris MJ, Rafelson WM, Krebs S, Moss NS. Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. J Neurooncol 163(2):455-462, 2023. e-Pub 2023. PMID: 37247180.
- Carter LM, Krebs S, Marquis H, Ocampo Ramos JC, Olguin EA, Mason EO, Bolch WE, Zanzonico PB, Kesner AL. Dosimetric variability across a library of computational tumor phantoms. J Nucl Med 64(5):782-790, 2023. e-Pub 2023. PMID: 37074039.
- Bodei L, Raj N, Do RK, Mauguen A, Krebs S, Reidy-Lagunes D, Schoder H. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of (177)Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med 64(4):567-573, 2023. e-Pub 2023. PMID: 36396457.
- Sponagel J, Jones JK, Frankfater C, Zhang S, Tung O, Cho K, Tinkum KL, Gass H, Nunez E, Spitz DR, Chinnaiyan P, Schaefer J, Patti GJ, Graham MS, Mauguen A, Grkovski M, Dunphy MP, Krebs S, Luo J, Rubin JB, Ippolito JE. Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment. Med 3(11):792-811.e12, 2022. e-Pub 2022. PMID: 36108629.
- Lafontaine D, Schmidtlein CR, Kirov A, Reddy RP, Krebs S, Schoder H, Humm JL. TriDFusion (3DF) image viewer. EJNMMI Phys 9(1):72, 2022. e-Pub 2022. PMID: 36258098.
- Imber BS, Young RJ, Beal K, Reiner AS, Giantini-Larsen AM, Krebs S, Yang JT, Aramburu-Nunez D, Cohen GN, Brennan C, Tabar V, Moss NS. Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neurooncol 159(3):609-618, 2022. e-Pub 2022. PMID: 35896906.
- Krebs S, Mauguen A, Yildirim O, Hatzoglou V, Francis JH, Schaff LR, Mellinghoff IK, Schoder H, Grommes C. Prognostic value of [(18)F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. Eur J Nucl Med Mol Imaging 48(12):3940-3950, 2021. e-Pub 2021. PMID: 33966087.
- Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Burnes Vargas D, Kubik TZ, Monette S, Santich BH, Yang G, Ouerfelli O, Kesner AL, Cheung NV, Scheinberg DA, Larson SM, Krebs S. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjug Chem 32(4):649-654, 2021. e-Pub 2021. PMID: 33819023.
- Carter LM, Choi C, Krebs S, Beattie BJ, Kim CH, Schoder H, Bolch WE, Kesner AL. Patient Size-Dependent Dosimetry Methodology Applied to (18)F-FDG Using New ICRP Mesh Phantoms. J Nucl Med 62(12):1805-14, 2021. e-Pub 2021. PMID: 33863823.
- Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, Pandit-Taskar N. Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 47(13):3047-3057, 2020. e-Pub 2020. PMID: 32378020.
- Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico P, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. J Nucl Med 61(11):1580-1587, 2020. e-Pub 2020. PMID: 32169913.
- Graham MS, Krebs S, Bale T, Domfe K, Lobaugh SM, Zhang Z, Dunphy MP, Kaley T, Young RJ. Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. Neurooncol Adv 2(1):vdaa050, 2020. e-Pub 2020. PMID: 32642703.
- Grkovski M, Goel R, Krebs S, Staton KD, Harding JJ, Mellinghoff IK, Humm JL, Dunphy MPS. Pharmacokinetic Assessment of (18)F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer. J Nucl Med 61(3):357-366, 2020. e-Pub 2020. PMID: 31601700.
Other Articles
- Imber BS, Yu KKH, Abida W, Pike LRG, Grkovski M, Kaley TJ, Morris MJ, Bodei L, Nosov A, Dunphy MPS, Schoder H, Fox JJ, Rosenblum M, Bale T, Krebs S Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617. J Nucl Med, 2025. PMID: 40049744.
- Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, Enderling H, Schoenfeld JD, Brody JD, McGee HM, Mondini M, Kent MS, Young KH, Galluzzi L, Karam SD, Theelen WSME, Chang JY, Huynh MA, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji QH, Nguyen AT, Patel RB, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera TA, Ong IM, Herrera F, Menon H, Smart D, Ahmed J, Gartrell RD, Roland CL, Fekrmandi F, Chakraborty B, Bent EH, Berg TJ, Hutson A, Khleif S, Sikora AG, Fong L Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol 26(3):e152-e170, 2025. PMID: 40049206.
- Glaviano, A, Lau, HH, Carter, LM, Lee, EC, Lam, HY, Okina, E, Tan, DJ, Tan, W, Ang, HL, Carbone, D, Yee, MH, Shanmugam, MK, Huang, XZ, Sethi, G, Tan, TZ, Lim, LH, Huang, RJ, Ungefroren, H, Giovannetti, E, Tang, DG, Bruno, TC, Luo, P, Andersen, MH, Qian, BZ, Ishihara, J, Radisky, DC, Elias, S, Yadav, S, Kim, M, Robert, C, Diana, P, Schalper, K, Shi, T, Merghoub, T, Krebs, SS, Kusumbe, AP, Davids, MS, Brown, JR, Kumar, AP Harnessing the tumor microenvironment. J Hematol Oncol 18(1), 2025. PMID: 39806516.
- Lovibond S, Gewirtz AN, Pasquini L, Krebs S, Graham MS The promise of metabolic imaging in diffuse midline glioma. Neoplasia 39:100896, 2023. PMID: 36944297.
- Krebs S, Schwartz J, Grommes C, Young RJ, Schoder H, Mayerhoefer ME Detecting CXCR4 Expression in Meningioma on (68)Ga-Pentixafor PET/MRI. J Nucl Med 64(4):667-668, 2023. PMID: 36357178.
- Imber BS, Young RJ, Beal K, Reiner AS, Giantini-Larsen AM, Krebs S, Yang JT, Aramburu-Nunez D, Cohen GN, Brennan C, Tabar V, Moss NS Correction to: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neurooncol 159(3):619, 2022. PMID: 35997921.
- Krebs S, Grommes C, McDevitt MR, Carlin SD, O'Donoghue JA, Graham MS, Young RJ, Schoder H, Gutin PH, Bander NH, Osborne JR Correction to: [(89)Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. Eur J Nucl Med Mol Imaging 49(6):2102, 2022. PMID: 35266033.
- Krebs S, Grommes C, McDevitt MR, Carlin SD, O'Donoghue JA, Graham MS, Young RJ, Schoder H, Gutin PH, Bander NH, Osborne JR [(89)Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. Eur J Nucl Med Mol Imaging 49(2):783-785, 2022. PMID: 34498111.
- Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 131(13), 2021. PMID: 34196303.
- Krebs S, Barasch JG, Young RJ, Grommes C, Schoder H Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. Ann Lymphoma 5, 2021. PMID: 34223561.
- Krebs S, Dacek MM, Carter LM, Scheinberg DA, Larson SM CAR Chase: Where Do Engineered Cells Go in Humans?. Front Oncol 10:577773, 2020. PMID: 33042849.
- Krebs S, Petkovska I, Ho AL, Ulaner GA Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT. Clin Nucl Med 45(8):654-655, 2020. PMID: 32433161.
- Glaviano A, Lau HS, Carter LM, Krebs S, Kumar AP Changing the course of EMT: prospects and caveats of TME-modulating cancer therapy. J Hematol Oncol.
Patient Reviews
CV information above last modified June 10, 2025